YONG LI to Lymphoma
This is a "connection" page, showing publications YONG LI has written about Lymphoma.
Connection Strength
1.301
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
Score: 0.587
-
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-?B activation and lymphomagenesis. Blood. 2021 03 25; 137(12):1615-1627.
Score: 0.538
-
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation. Blood. 2025 Mar 06; 145(10):1047-1060.
Score: 0.177